Therapeutic Advances in the Treatment of CLL: Focus on Inhibitors of the BCR Signaling Pathways
This information was originally presented on March 15, 2014, at the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.
This activity is designed to meet the educational needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Integrate into professional practice the key updates of the NCCN Guidelines related to chronic lymphocytic leukemia
- Describe the mechanism of action, as well as the main efficacy and safety results from clinical studies with the PI3K-delta inhibitor idelalisib and BTK inhibitor ibrutinib
John C. Byrd, MD
The Ohio State University Comprehensive Cancer Center –
James Cancer Hospital and Solove Research Institute
- 0.75 Participation
- 0.81 Nurse
- 0.75 Pharmacist
- 0.75 Physician